Return to the catalog
SS-31
NewIn Stock10mg vial

SS-31

Mitochondria-targeting peptide studied for cell energy and protection from oxidative stress.

For Research Use Only

Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.

1–4 vialsR 850.00
5+ vials — save 20%R 680.00 each

The lower price is applied automatically once your cart holds 5 or more of this vial.

Bacteriostatic water included

99%+ Purity
Extensively Researched
1

About this peptide

SS-31 is a targeted four-amino-acid peptide engineered to cross directly into the cell’s powerhouse—the mitochondria. It selectively binds to cardiolipin, an essential lipid that maintains the inner mitochondrial membrane. Research indicates this binding action helps repair disrupted mitochondrial structure, restores natural cellular energy (ATP) production, and neutralizes oxidative stress directly at the source.

Why researchers reach for SS-31

Cardiolipin binding

Selectively concentrates at the inner mitochondrial membrane.

ROS reduction

Lowers reactive oxygen species in mitochondrial assays.

ATP output

Restores ATP synthesis in aged / diseased mitochondria models.

Key features

  • ≥99% HPLC purity
  • Cardiolipin-targeted tetrapeptide
  • Mass-spec verified
  • Cold-chain dispatch

How it works

Membrane stabilization

Preserves cristae curvature and supercomplex integrity.

Electron transport support

Improves Complex I/IV coupling in preclinical work.

Peroxidase-like activity

Neutralizes cardiolipin peroxidation intermediates.

Research dosage guidelines

Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.

RangeReported doseNote
Reported research range1–10 mg/day, once dailyReference only
Higher research rangeUp to 40 mg/day, once dailyReference only
Typical reconstitution2 mL bacteriostatic waterYields 5 mg/mL (5000 mcg/mL)

Tracking this compound? Registered researchers can log active SS-31 protocols in their private Research Log.

Timing in research protocols

Once daily, continuous — no time-of-day requirement documented.

  • The TAZPOWER programme used 40 mg subcutaneously once daily, in 12-week crossover arms with a 4-week washout, followed by an open-label extension out to 168 weeks.
  • The FDA integrated review records the same once-daily regimen.
  • No specific clock time or meal relationship is specified in the trial documentation.
  • Endpoints improved progressively over months, so the studied pattern is long-term maintenance rather than a short cycle.

Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.

Technical specifications

Sequence
D-Arg-2,6-dimethylTyr-Lys-Phe-NH2
Molecular weight
639.8 g/mol
Purity
≥99% (HPLC)
Form
Lyophilized powder
Vial size
10 mg
Storage (lyophilised vial)
Cool, dry and protected from light
Storage (after reconstitution)
2–8°C

Published research

Peer-reviewed literature on SS-31. Links open in a new tab.

Research use notice

Sold for in vitro laboratory research only. Not for human or veterinary use, diagnosis, or therapy.

#mitochondrial#cardiolipin

Cart (0)

Your cart is empty